---
title: "Real-Time Benefit Checks for Specialty Drugs: Where We Are in 2026"
excerpt: "Real-time benefit checks promise instant coverage info at point of prescribing. For specialty drugs, the reality is more complicated."
coverImage: "/assets/blog/real-time-benefit-checks-specialty-drugs-2026/cover.svg"
date: "2026-04-16"
author:
  name: "Luma Team"
  picture: "/assets/blog/authors/luma-team.svg"
category: "Industry Insights"
ogImage:
  url: "/assets/blog/real-time-benefit-checks-specialty-drugs-2026/cover.svg"
---

<article>

# Real-Time Benefit Checks for Specialty Drugs: Where We Are in 2026

The promise of real-time benefit checks sounds straightforward: prescribe a drug, instantly see whether it's covered, what it costs the patient, and whether a prior authorization is required. No phone calls, no separate portal lookup, no waiting.

For standard medications, that promise is largely delivered. For specialty drugs and biologics, the picture is considerably more complicated — and understanding why matters if you're managing a high-volume biologic practice.

## What RTBC Actually Is

Real-time benefit checks (RTBC) are point-of-prescribing queries that pull live formulary and benefit data from a patient's pharmacy benefit manager or insurer. The technical standard is maintained by <a href="https://www.ncpdp.org/Resources/NCPDP-Resources/Standards-and-Implementation-Documents" target="_blank" rel="noopener">NCPDP</a> (National Council for Prescription Drug Programs), which defines the data exchange format that connects EHRs and prescribing tools to payer systems.

In practice, when a physician opens a prescribing workflow and selects a drug, an RTBC query fires automatically against the patient's active pharmacy benefit. Within seconds, the EHR surfaces:

- Whether the drug is covered under the patient's benefit
- The patient's estimated out-of-pocket cost
- Whether a prior authorization is required
- Alternative drugs on the formulary with lower cost or fewer PA requirements
- Pharmacy options (including specialty pharmacies, when applicable)

The major EHR vendors — Epic, Oracle Health, Athenahealth — have RTBC integrated into prescribing workflows for enrolled payers. <a href="https://www.surescripts.com/about-surescripts/what-we-do/real-time-benefit-check" target="_blank" rel="noopener">Surescripts</a> is the primary network aggregating payer connections, with coverage across most major pharmacy benefit managers.

For primary care medications — antihypertensives, statins, common antibiotics — this works well. The data is clean, the cost information is accurate, and the PA flag is reliable.

## Where Specialty Drugs Break the Model

Specialty drugs occupy a different tier of complexity, and RTBC handles that complexity inconsistently.

The first issue is **benefit architecture**. Many specialty drugs — particularly biologics like TNF inhibitors, IL-17 inhibitors, and JAK inhibitors — are covered under the medical benefit, not the pharmacy benefit. RTBC queries the pharmacy benefit. If your biologic is billed as a medical benefit infusion or injection, the query either returns no data or returns pharmacy benefit data that doesn't reflect actual coverage.

Some manufacturers have worked with payers to create specialty-specific RTBC pathways. NCPDP's RTBC standard does include specialty drug fields. But payer implementation is inconsistent — some major PBMs have robust specialty data in their RTBC feeds; others surface incomplete or outdated formulary information for these drugs.

The second issue is **PA complexity**. RTBC can tell you that a PA is required. It cannot tell you what that PA requires. For a standard drug, that's a minor limitation — the PA might be simple enough that the flag alone is sufficient information. For adalimumab or ustekinumab, knowing a PA is required tells you almost nothing useful. The actual requirements span:

- Specific diagnosis codes with sufficient clinical specificity
- Disease activity scores at defined thresholds
- Documented failure of multiple prior therapies in sequence
- Lab values within defined time windows
- Specialist involvement attestations

None of that complexity is surfaced through an RTBC query. The PA flag is a starting point, not a roadmap.

The third issue is **timeliness of specialty data**. Formulary changes for specialty drugs happen frequently — payer preferred product lists shift, biosimilar additions change the PA calculus, and step therapy requirements get updated mid-year. RTBC data depends on payers pushing current formulary files. Specialty drug formulary files lag more often than standard drug files, meaning the RTBC response for a biologic may reflect requirements that were updated weeks or months ago.

## Current Adoption Rates

RTBC adoption for standard drugs is high. <a href="https://www.surescripts.com/news-and-events/press-releases/" target="_blank" rel="noopener">Surescripts</a> has reported billions of RTBC transactions processed annually, with coverage across the vast majority of commercially insured lives in the US.

Specialty drug RTBC coverage is narrower. The major integrated PBMs — Express Scripts (Evernorth), CVS Caremark, OptumRx — have specialty RTBC data in their feeds, but completeness and accuracy vary by therapeutic category. Rheumatology and dermatology biologics have better coverage than some newer categories like gastroenterology biologics or gene therapies, where PA requirements are more individualized.

A meaningful minority of specialty RTBC queries return a "unable to determine" response — which is better than wrong information, but not useful for clinical decision-making. Practices that have measured their RTBC response rates for specialty drugs often find 20-30% of queries returning incomplete or null coverage data for their specific biologic portfolios.

## Where the Technology Is Heading

The most meaningful development on the horizon is the integration of RTBC with FHIR-based PA workflows. The Da Vinci CRD (Coverage Requirements Discovery) implementation guide goes further than RTBC by pulling not just whether a PA is required, but what the payer's specific documentation requirements are — in structured, queryable form.

When CRD is implemented alongside RTBC, the prescribing workflow becomes: drug selected → coverage confirmed (RTBC) → PA requirements retrieved in real time (CRD) → documentation questionnaire pre-populated from the chart (DTR). That's a materially different experience from today's point-of-prescribing flow.

The <a href="https://www.cms.gov/regulations-and-guidance/regulations/interoperability-prior-authorization" target="_blank" rel="noopener">CMS January 2027 FHIR PA API mandate</a> will push payers to build the infrastructure that makes this possible for Medicare Advantage and Medicaid. Commercial payer adoption will follow, but on its own timeline.

Biosimilar adoption is also reshaping the specialty RTBC landscape. As <a href="https://www.fda.gov/drugs/biosimilars/biosimilar-product-information" target="_blank" rel="noopener">FDA-approved biosimilars</a> become preferred products on formulary and originator biologics face step therapy requirements, the RTBC data becomes more important — and more dynamic. Practices managing patients across multiple biologic options need current preferred-product status at prescribing time, and payer formulary changes are happening faster than RTBC data pipelines can always track.

## What RTBC Can and Can't Do for Your Practice

Honest framing: RTBC is a triage tool, not a PA solution.

For specialty drugs, a positive RTBC hit — drug is covered, PA required — tells you to start the PA process. It doesn't tell you whether your existing clinical documentation is sufficient, whether the patient has satisfied step therapy requirements in a way that's documented adequately, or what specific lab values the payer needs to see.

That gap is where the actual work happens. RTBC initiates; documentation quality determines whether the PA succeeds.

Platforms like <a href="https://useluma.io/blog" target="_blank" rel="noopener">Luma</a> sit in that gap — taking the clinical data that exists in a chart and transforming it into documentation that meets the specific criteria that an RTBC flag only hints at. RTBC tells you a PA is needed. Complete, payer-specific medical necessity documentation is what gets it approved.

Used together, RTBC and specialized documentation tools create a workflow where prescribers get coverage information at the point of decision, and the documentation process that follows is structured around what the payer actually needs — not a generic template that may or may not satisfy criteria.

## The Bottom Line for 2026

RTBC is more useful than it was two years ago, and it will be more useful still in two more. For standard drugs, it's already close to the seamless point-of-prescribing coverage check it was designed to be.

For specialty drugs and biologics: treat RTBC as a signal, not an answer. The drug may be covered. The PA may be required. What happens next — the documentation, the clinical evidence, the structured argument for medical necessity — is still a distinct process that RTBC doesn't touch.

Practices that understand this distinction will use RTBC effectively without expecting it to solve problems it wasn't designed for.

---

<p style="font-size: 9px; color: #888; margin-top: 2rem;">
<strong>Sources:</strong><br>
NCPDP. (2025). <em>Real-Time Benefit Check Standard Documentation.</em> <a href="https://www.ncpdp.org/Resources/NCPDP-Resources/Standards-and-Implementation-Documents" target="_blank" rel="noopener">ncpdp.org</a><br>
Surescripts. (2025). <em>Real-Time Benefit Check: Network Overview and Adoption Data.</em> <a href="https://www.surescripts.com/about-surescripts/what-we-do/real-time-benefit-check" target="_blank" rel="noopener">surescripts.com</a><br>
Centers for Medicare &amp; Medicaid Services. (2024). <em>CMS Interoperability and Prior Authorization Final Rule.</em> <a href="https://www.cms.gov/regulations-and-guidance/regulations/interoperability-prior-authorization" target="_blank" rel="noopener">cms.gov</a><br>
FDA. (2025). <em>Biosimilar Product Information.</em> <a href="https://www.fda.gov/drugs/biosimilars/biosimilar-product-information" target="_blank" rel="noopener">fda.gov</a><br>
HL7 Da Vinci Project. (2025). <em>Coverage Requirements Discovery Implementation Guide.</em> <a href="https://www.hl7.org/about/davinci/" target="_blank" rel="noopener">hl7.org/about/davinci</a>
</p>

</article>
